Fitch Ratings anticipates that changes to the asset management regulatory framework enacted by the Brazilian Securities and Exchange Commission (CVM) recently will modernize the country's asset management industry while also simplifying relationships among agents and increasing transparency.
A special report recently released by the globally recognized statistical rating organizations predicted the CVM's much-anticipated easing of limits for investments abroad will be beneficial for the development of the Brazilian asset management industry now that investors will be able to increase the diversification of their portfolios.
Another highly anticipated change was a revision to service providers' compensation, which prohibits any type of kickback or rebate to portfolio managers that would affect their decision making unless regulators see no conflict of interest, such as in the cases of mirror funds. In making the change, the CVM is trying to align with international practices and improve overall transparency.
Other changes more clearly outline the responsibilities between fund administrators and managers; add new manager responsibilities; and clarify the rules that must be observed in relation to co-managed portfolios.
Organizations in this Story
Want to get notified whenever we write about Fitch Ratings ?
Next time we write about Fitch Ratings, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.Sign-up for Alerts
- New Colombia Resources says Sannabis test was successful
- Grupo Exito aims to help support Colombia
- Codelco CEO calls for transparency, focus on production goals
- BCP offers tips on choosing master's degree program
- General Tire launches new tire for Andean market
- Latin America talks of boosting pork production, exports @CorferiasBogota
- AIR Worldwide team takes part in wind-engineering conference
- El Salvador's Asesuisa discusses risk management, strategic direction with stakeholders
- Grupo Exito buying lettuce locally to support resocialization program
- Endo selling Mexico-based Grupo-Farmaceutico Somar